Bayer’s Kerendia demonstrates success in phase 3 clinical trials for treatment of heart failure
A phase 3 trial showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo. Hyperkalemia was greater ...
Tag: MRAs
#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...